文献速递心脑血管急症重症综合管理与镇静镇痛

氢气吸入联合低温目标温度管理改善院外心脏骤停结局:HYBRID II试验事后分析

Combination of Hydrogen Inhalation and Hypothermic Temperature Control After Out-of-Hospital Cardiac Arrest: A Post hoc Analysis of the Efficacy of Inhaled Hydrogen on Neurologic Outcome Following Brain Ischemia During PostCardiac Arrest Care II Trial.
PubMed 文献 · Crit Care Med · 2024-08-12
一句话结论在心脏源性院外心脏骤停患者中,氢气吸入联合32-34°C目标温度管理与更好的90天神经功能结局独立相关。

该研究为多中心随机对照试验HYBRID II的事后分析,纳入15个日本ICU中心72例心脏源性院外心脏骤停患者(氢气组39例,对照组33例),比较氢气混合氧与纯氧吸入在目标温度管理(TTM)32-34°C或35-36°C下的效果。在TTM32-34°C亚组中,氢气组17例(68%)与对照组9例(38%)达到90天良好神经功能结局(相对风险1.81,95%CI 1.05-3.66,p<0.05),氢气+TTM32-34°C与良好神经功能结局独立相关(校正比值比16.10,95%CI 1.88-138.17,p=0.01)。但氢气+TTM32-34°C与单用TTM32-34°C相比未改善生存(校正风险比0.22,95%CI 0.05-1.06,p=0.06)。作者认为氢气吸入联合TTM32-34°C是减少心脏骤停后脑损伤的有前景的治疗选择。

要点

  • 在TTM32-34°C亚组中,氢气组90天良好神经功能结局68%(17/25)vs 对照组38%(9/24),相对风险1.81(95%CI 1.05-3.66),p<0.05。
  • 氢气+TTM32-34°C与良好神经功能结局独立相关,校正比值比16.10(95%CI 1.88-138.17),p=0.01。
  • 氢气+TTM32-34°C与单用TTM32-34°C相比未改善90天生存,校正风险比0.22(95%CI 0.05-1.06),p=0.06。
  • 氢气组与对照组TTM32-34°C实施比例分别为64%(25例)和73%(24例),p=0.46。

适用人群与场景

  • 入选HYBRID II试验的心脏源性院外心脏骤停患者,来自15个日本ICU中心,共72例(氢气组39例,对照组33例)具有结局数据。

处置流程与药物剂量

  • 氢气组吸入氢气混合氧,对照组吸入纯氧。
  • 按各机构方案实施目标温度管理,目标温度32-34°C(TTM32-TTM34)或35-36°C(TTM35-TTM36)。

研究设计与关键结果

  • 研究设计为多中心随机对照试验的事后分析,纳入15个日本ICU中心的72例心脏源性院外心脏骤停患者(氢气组39例,对照组33例)。
  • TTM32-TTM34在氢气组和对照组分别有25例(64%)和24例(73%)实施(p=0.46)。
  • 在TTM32-TTM34下,氢气组17例(68%)和对照组9例(38%)达到90天良好神经功能结局(相对风险1.81,95%CI 1.05-3.66,p<0.05)。
  • 氢气+TTM32-TTM34与良好神经功能结局独立相关(校正比值比16.10,95%CI 1.88-138.17,p=0.01)。
  • 氢气+TTM32-TTM34与单用TTM32-TTM34相比未改善生存(校正风险比0.22,95%CI 0.05-1.06,p=0.06)。

证据类型、等级与局限

  • 证据类型:多中心随机对照试验的事后分析。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,氢气吸入联合TTM32-34°C是减少心脏骤停后脑损伤的有前景的治疗选择。
  • 在TTM32-TTM34条件下,氢气+TTM32-TTM34与更好的90天神经功能结局独立相关(校正比值比16.10,95%CI 1.88-138.17,p=0.01),但未改善90天生存(校正风险比0.22,95%CI 0.05-1.06,p=0.06)。

指南或共识出处

  • HYBRID II试验(jRCTs031180352)。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVE: The Efficacy of Inhaled Hydrogen on Neurologic Outcome Following Brain Ischemia During Post-Cardiac Arrest Care (HYBRID) II trial (jRCTs031180352) suggested that hydrogen inhalation may reduce post-cardiac arrest brain injury (PCABI). However, the combination of hypothermic target temperature management (TTM) and hydrogen inhalation on outcomes is unclear. The aim of this study was to investigate the combined effect of hydrogen inhalation and hypothermic TTM on outcomes after out-of-hospital cardiac arrest (OHCA).

DESIGN: Post hoc analysis of a multicenter, randomized, controlled trial.

SETTING: Fifteen Japanese ICUs.

PATIENTS: Cardiogenic OHCA enrolled in the HYBRID II trial.

INTERVENTIONS: Hydrogen mixed oxygen (hydrogen group) versus oxygen alone (control group).

MEASUREMENTS AND MAIN RESULTS: TTM was performed at a target temperature of 32-34°C (TTM32-TTM34) or 35-36°C (TTM35-TTM36) per the institutional protocol. The association between hydrogen + TTM32-TTM34 and 90-day good neurologic outcomes was analyzed using generalized estimating equations. The 90-day survival was compared between the hydrogen and control groups under TTM32-TTM34 and TTM35-TTM36, respectively. The analysis included 72 patients (hydrogen [ n = 39] and control [ n = 33] groups) with outcome data. TTM32-TTM34 was implemented in 25 (64%) and 24 (73%) patients in the hydrogen and control groups, respectively ( p = 0.46). Under TTM32-TTM34, 17 (68%) and 9 (38%) patients achieved good neurologic outcomes in the hydrogen and control groups, respectively (relative risk: 1.81 [95% CI, 1.05-3.66], p < 0.05). Hydrogen + TTM32-TTM34 was independently associated with good neurologic outcomes (adjusted odds ratio 16.10 [95% CI, 1.88-138.17], p = 0.01). However, hydrogen + TTM32-TTM34 did not improve survival compared with TTM32-TTM34 alone (adjusted hazard ratio: 0.22 [95% CI, 0.05-1.06], p = 0.06).

CONCLUSIONS: Hydrogen + TTM32-TTM34 was associated with improved neurologic outcomes after cardiogenic OHCA compared with TTM32-TTM34 monotherapy. Hydrogen inhalation is a promising treatment option for reducing PCABI when combined with TTM32-TTM34.

来源:Crit Care Med,查看原文。版权归原作者所有。

参考来源

  1. Tamura T, Narumiya H, Homma K, et al. Combination of Hydrogen Inhalation and Hypothermic Temperature Control After Out-of-Hospital Cardiac Arrest: A Post hoc Analysis of the Efficacy of Inhaled Hydrogen on Neurologic Outcome Following Brain Ischemia During PostCardiac Arrest Care II Trial. Crit Care Med. 2024. PMID: 39133068. doi:10.1097/CCM.0000000000006395

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。